ArticleVox sanguinis2025
Three buffy coat platelet concentrates: Use of data modelling to make more with less.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three buffy coat platelet concentrates: Use of data modelling to make more with less.Vox sanguinis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe Welsh Blood Service (WBS) produces pooled platelet concentrates from four buffy coats (4BC-PC), achieving consistently high platelet yields exceeding the UK specification. Three buffy coat platelet concentrates (3BC-PC) offer the potential for improved supply chain resilience and increased production capacity. Data modelling was performed to evaluate the local feasibility of 3BC-PC production. MATERIALS AND
methodsPlatelet recovery (%) was calculated from 41 4BC-PC to generate three reference values (maximum, average and minimum). Measurements from the 164 BCs were used to model 3BC-PC production, with further analysis determining the impacts of manufacturing variability. Calculated yields were assessed against UK, European (EU) and UK contingency specifications. Potential production increases for WBS were estimated alongside statistical significance and effect size of the modelling.
resultsData modelling with 3BC-PC showed 100% compliance against UK minimum requirements approved as a contingency measure (≥75% achieving ≥150 × 10
conclusionData modelling supports 3BC-PC as a feasible alternative to 4BC-PC, offering increased production capacity. Modelled 3BC-PC met UK contingency and EU specifications. Compliance with the UK standard specification was variable and suggests the need for further optimization. Real-world validation would confirm whether this is a practical proposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.